ATLANTA, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the following upcoming conferences:
- Rodman & Renshaw 18th Annual Global Investment Conference at 4:15 p.m. ET on Tuesday, September 13, 2016 in New York, NY. Link: http://wsw.com/webcast/rrshq26/avir
- Ladenburg Thalmann 2016 Healthcare Conference at 2:30 p.m. ET on Tuesday, September 27, 2016 in New York, NY. Link: http://wsw.com/webcast/ladenburg2/avir
A live audio webcast of each presentation can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.aviragentherapeutics.com. An archived replay of the webcast will be available for 30 days after the live event concludes.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 firstname.lastname@example.org Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 email@example.com
Source:Aviragen Therapeutics, Inc.